Nektar Therapeutics' autoimmune disease drug fails mid-stage study
Nektar Therapeutics said on Thursday its experimental drug, developed in collaboration with Eli Lilly, to treat autoimmune disease systemic lupus erythematosus had failed to the meet primary goal in a mid-stage study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.